ProfileGDS5678 / 1433445_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 96% 96% 97% 95% 95% 97% 97% 97% 96% 97% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.427195
GSM967853U87-EV human glioblastoma xenograft - Control 28.6675695
GSM967854U87-EV human glioblastoma xenograft - Control 39.1423496
GSM967855U87-EV human glioblastoma xenograft - Control 49.2108796
GSM967856U87-EV human glioblastoma xenograft - Control 59.2719897
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.1617195
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.1883395
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.030997
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.4358197
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.3663697
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.8023396
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.1829397
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.0934996
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.0560296